Elaine Quilici

Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, talks purpose and perseverance—both in her own career journey and her group’s mission to topple barriers to drug access in diverse and hard-to-reach regions.

For leaders, shifting mindsets and altering dynamics can help.

Yan Chen, CEO of Elpis Biopharmaceuticals, talks about how she transitioned her career from scientist to CEO and what that has entailed.

Arthur Kuan, CEO of CG Oncology, talks about the present and future of bladder cancer therapies, and how he’s committed to making a difference.

Latino executives share their experiences and insights on the community’s contributions to the life sciences industry.

Give your team members opportunities to lead for greater growth.

Looking back at 2000-2002.

Emma Chaffin, vice president and country head of Galapagos UK, discusses how her personal journey with cancer put a spin on her life, including her career in pharma.

Teresa Bitetti, President of Takeda Pharmaceuticals’ Global Oncology Business Unit, talks about her experience as a leader in the oncology space and what that entails in today’s environment.

Judy Stewart, head of US vaccines at GSK, talks about the effects of people missing their recommended vaccinations during the pandemic and the importance of delivering a message of value for vaccines.

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

Mike Starich, CEO of Orion Talent, and Dr. Armand Balboni, CEO of Appili Therapeutics, talk about hiring veterans for roles in pharma, and how the industry can capitalize on their unique qualifications.

Sandor Schoichet, an independent advisor and director of Meridian Management Consultants based in San Francisco, and Thomas Scheiwiller, an independent advisor and board member based in Zurich, talk about integrating environmental, social, and governance, or ESG, issues into biopharma business planning, and communicating with capital investors about these areas.

Learning from others and leading by example provides full-circle success.

Startup CEO touts immunology technology to cure cancer and more.

Academic-focused leader advocates questioning and communicating to advance science.

A deeper understanding of the differing age-group dynamics is key.

Dr. Michele Cleary, CEO of the Mark Foundation for Cancer Research, discusses how the foundation has navigated COVID to help keep critical cancer research going throughout the pandemic.

John Furey, CEO of Imvax and an Editorial Advisory Board member for Pharm Exec, discusses some leadership principles he learned while playing rugby as a young man in Ireland, and how those tenets can translate to the C-suite.

The Healthcare Businesswomen’s Association again names Sandra Horning its WoTY—where the pharma leader’s message of purpose and partnership takes on added resonance today.

How open, two-way communication can help leaders to improve.

Uche Iloeje, Vice President medical affairs Mirdametenib at SpringWorks Therapeutics, shares his experience after he became stranded in Nigeria for five months and the valuable leadership lessons he learned.

Paul Shawah, Executive Vice President of Strategy at Veeva Systems, looks back at the past year of the pandemic to see the digital transformation of pharma’s interaction with healthcare professionals.

Michael Bailey, CEO of AVEO Oncology, discusses how his ultimate leadership path in biotech—the setbacks and “long slog of ups and downs”—continues to shape a patient-focused mission on bridging product development and commercialization to advance drugs for unmet need in cancer.

Open communication gives people the opportunity to explore.

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent with the firm, discuss IP strategy as it relates to pharma and artificial intelligence.

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.

Looking back at 1982-1985.

Creating stronger relationships can set off a chain of success.